Free fatty acids induce ER stress and block antiviral activity of interferon alpha against hepatitis C virus in cell culture

Virology Journal

Srikanta Dash¹  Luis A Balart³  Darren P Baker²  Bret Poat¹  Sidhartha Hazari¹  Partha K Chandra¹  Fatma M Aboulnasr¹  Feyza Gunduz³ 

[1] Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA, 70112, USA;Biogen Idec Inc., Cambridge, MA, 02142, USA;Department of Medicine, Gastroenterology and Hepatology, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA, 70112, USA

关键词: Jak-Stat signaling;    Endoplasmic reticulum stress;    IFN alpha;    Hepatic steatosis;    Free fatty acids;    Hepatitis C virus;   

Others  :  1154284
DOI  :  10.1186/1743-422X-9-143

 received in 2011-10-19, accepted in 2012-07-27,  发布年份 2012

【 摘 要 】

Background

Hepatic steatosis is recognized as a major risk factor for liver disease progression and impaired response to interferon based therapy in chronic hepatitis C (CHC) patients. The mechanism of response to interferon-alpha (IFN-α) therapy under the condition of hepatic steatosis is unexplored. We investigated the effect of hepatocellular steatosis on hepatitis C virus (HCV) replication and IFN-α antiviral response in a cell culture model.

Methods

Sub-genomic replicon (S3-GFP) and HCV infected Huh-7.5 cells were cultured with a mixture of saturated (palmitate) and unsaturated (oleate) long-chain free fatty acids (FFA). Intracytoplasmic fat accumulation in these cells was visualized by Nile red staining and electron microscopy then quantified by microfluorometry. The effect of FFA treatment on HCV replication and IFN-α antiviral response was measured by flow cytometric analysis, Renilla luciferase activity, and real-time RT-PCR.

Results

FFA treatment induced dose dependent hepatocellular steatosis and lipid droplet accumulation in the HCV replicon cells was confirmed by Nile red staining, microfluorometry, and by electron microscopy. Intracellular fat accumulation supports replication more in the persistently HCV infected culture than in the sub-genomic replicon (S3-GFP) cell line. FFA treatment also partially blocked IFN-α response and viral clearance by reducing the phosphorylation of Stat1 and Stat2 dependent IFN-β promoter activation. We show that FFA treatment induces endoplasmic reticulum (ER) stress response and down regulates the IFNAR1 chain of the type I IFN receptor leading to defective Jak-Stat signaling and impaired antiviral response.

Conclusion

These results suggest that intracellular fat accumulation in HCV cell culture induces ER stress, defective Jak-Stat signaling, and attenuates the antiviral response, thus providing an explanation to the clinical observation regarding how hepatocellular steatosis influences IFN-α response in CHC.

【 授权许可】

   
2012 Gunduz et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:27-34.
• [2]Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2006, 5:558-567.
• [3]Deuffic S, Poynard T, Valleron AJ: Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepat 1999, 6:411-413.
• [4]Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
• [5]Gao B, Hong F, Radaeva S: Host factors and failure of interferon alpha treatment in hepatitis C virus. Hepatology 2004, 39:880-890.
• [6]Puri P, Sanyal AJ: Role of obesity, insulin resistance and steatosis in hepatitis C virus infection. Clin Liver Dis 2006, 10:703-819.
• [7]Sanyal A: Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Liver Int 2011, 31:23-28.
• [8]Negro F, Clement S: Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat 2009, 16:681-688.
• [9]Alberti A: What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int 2009, 29:15-18.
• [10]Dash S, Prabhu R, Hazari S, Luo G, Bastian F, Garry RF, Zou W, Haque S, Joshi B, Regenstein FG, Thung SN: Interferon alpha, beta, gamma each inhibits hepatitis C virus replication at the levels of internal ribosome entry site mediated translation. Liver Int 2005, 25:1-15.
• [11]Guo J, Zhu Q, Seeger C: Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus sub genomic replicons. J Virol 2003, 77:10769-10779.
• [12]Cheney IW, Lai VCH, Zhong W, Brodhag T, Dempsey S, Lim C, Hong Z, Lau JYN, Tam RC: Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J Virol 2002, 76:11148-11154.
• [13]Vrolijk JM, Kaul A, Hanson BE, Lohmann V, Haagmans BL, Schalm SW, Bartenschalager R: A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J Virol Methods 2003, 110:201-209.
• [14]Wang C, Pflugheber J, Sumpter R, Sodora DL, Hui D, Sen G, Gale M: Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 2003, 77:3898-3912.
• [15]Negro F: Abnormalities of lipid metabolisms in hepatitis C virus infection. Gut 2010, 59:1279-1287.
• [16]Negro F: Mechanisms of hepatitis C virus-related insulin resistance. Clin Res Hepatol Gastroenterol 2011, 35:358-363.
• [17]Walch MJ, Johnson JR, Richardson MM, Lipka GM, Clouston AD, Powell EE: Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55:529-535.
• [18]Bressler BL, Guindi M, Tomlinson G, Heathcote J: High body mass index is an independent risk factor for nonresponsive to antiviral treatment in chronic hepatitis C. Hepatology 2003, 38:639-644.
• [19]Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jansson JR, Powell EE: Steatosis and liver cell apoptosis in chronic hepatitis C: A mechanism for increased liver injury. Hepatology 2004, 39:1230-1238.
• [20]Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J: Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004, 106:635-643.
• [21]Hazari S, Chandra PK, Poat B, Datta S, Garry RF, Foster TP, Kousoulas G, Wakita T, Dash S: Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. Virol J 2010, 7:36. BioMed Central Full Text
• [22]Gomez-Lechon MJ, Donato MT, Martinez-Romero A, Jimenez N, Castell JV: O Conner J-E: A human hepatocellular in vitro model to investigate steotosis. Chem Biol Interact 2007, 165:106-116.
• [23]Ricci M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, Bertolitti M, Banni S, Lenardo A, Carulli N, Loria P: Differential effect of oleic acid and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterology Hepatol 2009, 24:830-840.
• [24]Karaskov E, Scott C, Zhang L, Teodoro T, Ravazzola M, Volchuk A: Chronic palmitate but not the oleate exposure induces endoplasmic reticulum stress which may contribute to IRS-1 pancreatic b-cell apoptosis. Endocrinology 2005, 147:3398-3407.
• [25]Donato MT, Lahoz A, Jimenez N, Perez G, Serralta A, Mir J, Castell JV, Gomez-Lechon MJ: Potential impact of steatosis on cytochrome p450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos 2006, 34:1556-1562.
• [26]Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ: Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003, 39:978-983.
• [27]Bao L, Haque A, Jackson K, Hazari S, Moroz K, Jetley R, Dash S: Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in 4 T1 metastatic breast cancer model. Am J Pathol 2011, 178:838-852.
• [28]Chandra PK, Hazari S, Poat B, Gunduz F, Prabhu R, Liu G, Burioni R, Clementi M, Garry RF, Dash S: Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. Virol J 2010, 7:118. BioMed Central Full Text
• [29]Liu S, Nelson CA, Xiao L, Lu L, Seth PP, Davis DR, Hagedorn CH: Measuring antiviral activity of benzimidazole molecules that alters IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase. Antiviral Res 2011, 89:54-63.
• [30]Wei Y, Wang D, Topczewski F, Pagliassotti MJ: Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 2006, 291:275-281.
• [31]Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun CZ, Glimcher LH, Hotamisligil GS: Endoplamsic reticulum stress links obesity, insulin action and type 2 diabetes. Science 2004, 306:457-461.
• [32]Kanai K, Kako M, Okamoto H: HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992, 339:1543.
• [33]Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Ilotova V, Benhamou JP, Erlinger S: Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to interferon therapy in chronic hepatitis C. Hepatology 1995, 22:1050-1056.
• [34]Poynard T, Ratziu V, McHutchinson J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J: Effect of treatment with peg interferon or interferon alpha 2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38:75-85.
• [35]Monto A, Alonzo J, Watson JJ, Grunfeld G, Wright TL: Steatosis in chronic hepatitis C: relative contribution of obesity, diabetes mellitus and alcohol. Hepatology 2001, 36:729-736.
• [36]Asselah T, Rubbia-Brandt L, Marcellini P, Negro F: Steatosis in chronic hepatitis C: why does it really matter? Gut 2005, 55:123-130.
• [37]Mihm S, Fayyazi A, Hartmann H, Ramodori G: Analysis of histopathological manifestation of chronic HCV infection with respect to virus genotype. Hepatology 1997, 25:735-739.
• [38]Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C: Hepatitis C virus core protein and very low density lipoprotein secretion: a model of viral related steatosis. FASEB J 2002, 16:185-194.
• [39]Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, Zeuzem S, Schalm SW, Verheij-Hart E, Negro F, Missale G, Neumann AU: Hellstrand K; DITTO-HCV Study Group: Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 2007, 14:29-35.
• [40]Wu Y-J, Chen L-S, Qiang WG: Effect of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int 2006, 26:166-172.
• [41]Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, Vuturo O, Montalto G: Impact of liver steatosis on the antiviral response in the hepatitis C virus–associated chronic hepatitis C. Liver Int 2006, 26:1119-1125.
• [42]Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S, Conrad A, Pockros PJ, McHutchison JG: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004, 40:484-490.
• [43]Thomopoulos KC, Theocharis GJ, Tsamantas AC, Siagris D, Mimitropoulou D, Gogos CA, Labropoulou-Karatza C: Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2005, 27:149-153.
• [44]Kapadia SB, Chisari FV: Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005, 102:2561-2566.
• [45]Datta S, Hazari S, Chandra PK, Samara M, Poat B, Gunduz F, Wimley WC, Hauser H, Koster M, Lamaze C, Balart L, Garry RF, Dash S: Mechanisms of HCV’s resistance to IFN-alpha in cell culture involves expression of functional IFN-alpha receptor 1. Virol J 2011, 8:351. BioMed Central Full Text
• [46]Liu J, HuangFu WC, Kumar KG, Qian J, Casey JP, Hamanaka RB, Grigoriadou C, Aldabe R, Diehl JA, Fuchs SY: Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe 2009, 5(1):72-83.
• [47]Minakshi R, Padhan K, Rani M, Khan N, Ahmad F, Jameel S: The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor. PLoS One 2009, 17(4):e8342.
• [48]Taniguchi H, Iwasaki Y, Takahashi A, Shimomura H, Moriya A, Yu PC, Umeoka F, Fujioka S, Koide N, Shiratori Y: Intrahepatic mRNA levels of type I interferon receptor and interferon stimulated genes in genotype 1b chronic hepatitis C. Intervirology 2007, 50:32-39.
• [49]Morita K, Tanaka K, Saito S, Kitamura T, Kondo M, Sakaguchi T, Morimoto M, Sekihara H: Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection. J Clin Gastroenterol 1998, 26:135-140.
• [50]Fujiwara D, Hino K, Yamaguchi Y, Kubo Y, Yamashita S, Uchida K, Konishi T, Nakamura H, Korenaga M, Okuda M, Okita K: Type 1 interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. J Viral Hepat 2004, 11:136-140.
• [51]Meng XW, Chi BR, Chen LG, Zhang LL, Zhuang Y, Huang HY, Sun X: Expression of interferon-alpha/beta receptor protein in liver of patients with hepatitis C virus –related chronic liver disease. World J Gastroenterol 2005, 11:3962-3965.
• [52]Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT: O'Brien TR; HALT-C Trial Group: Variants in Interferon-alpha pathway genes and response to pegylated interferon-alpha 2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C Antiviral Long-term treatment against Cirrhosis trial. Hepatology 2009, 49:1847-1858.